Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia
Pacific Patients with Locally Advanced/Metastatic Non-Small Cell Lung Cancer whose Disease
has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor
Receptor Gene